IMCR
Immunocore Holdings Ltd
29.70$
-2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +349.4% | -19.9% | -9.6% | -1.1% | +25.6% | -19.8% | +106.5% | +29.3% | +13.3% | +69.1% | +5.7% | |
| – | +322.1% | -16.5% | -23.9% | +17.8% | -3.8% | -7.1% | +131.9% | +33.7% | +11.6% | +75.8% | +7.2% | |
| – | +332.7% | -39.0% | -37.5% | +48.1% | -21.2% | +80.4% | +81.6% | +25.4% | +10.0% | +3.0% | +2.6% | |
| – | +332.7% | -19.8% | -32.8% | +4.9% | -21.2% | +80.4% | +81.6% | +25.4% | +10.0% | +85.3% | +5.3% | |
| – | -8.2% | +130.8% | -99.1% | +107,820.1% | +1,415.8% | -96.9% | +1,534.6% | +70.3% | +7.6% | +35.3% | -11.0% | |
| – | – | – | – | – | – | – | – | – | +550.4% | +21.0% | +23.8% | |
| – | – | – | +116.2% | -12.7% | +162.9% | -32.9% | -14.4% | +0.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -31.3% | +161.6% | +99.8% | -57.2% | – | – | – | -100.0% | – | – | – | |
| – | -6.3% | -25.3% | +37.2% | +130.1% | +62.6% | -37.3% | +23.9% | +6.9% | +21.5% | +184.4% | +5.8% | |
| – | +21.6% | -3.7% | +38.3% | +64.5% | +125.7% | -50.9% | +50.1% | +22.1% | +37.9% | +52.6% | +16.3% | |
| – | – | – | – | – | – | -54.9% | -86.6% | +11.1% | -26.2% | +11.5% | +29.7% | |
| – | +338.6% | -14.1% | +162.1% | -20.9% | +223.4% | -62.2% | +28.4% | +42.8% | +23.2% | +41.0% | -2.9% | |
| – | – | – | – | – | – | – | +1.6% | +6.1% | +21.5% | +714.4% | +0.5% | |
| – | – | -18.4% | -21.4% | -58.9% | -65.4% | +182.8% | +318.3% | +46.4% | +8.8% | -2.2% | +5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +0.4% | +1,010.3% | +0.0% | +16.4% | +38.0% | +4.2% | +6.9% | +2.3% | +0.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.